$HCA - grabbing the falling knife.(?)

One policy question drives the whole fan: does Congress extend the ACA enhanced premium tax credits? They expired Jan 1, 2026, and HCA guided a $600–900M gross EBITDA hit for the year (mitigated to ~$200–500M net) on a 15–20% drop in exchange volumes, ~80–85% of which becomes uninsured. Crucially the damage is back-end-loaded: CBO has the uninsured count rising ~2.2M in 2026 but ~3.7M in 2027, so the bear rail actually dips through 2027 ($314→$273→$254) before the buyback and volume growth pull it back. The rails are the fork: bull/blue assume extension (the headwind reverses, EBITDA reaccelerates — bull ~$1754, +17%/yr); base/bear assume expiration (base = the mitigated guide path to ~$1126, +12%/yr; bear = full damage + DSH cuts + 2028 provider-tax limits, ~$545, +4%/yr). The reverse-DCF shows how negative the market already is: at $365 the EV (~$129b incl. ~$48b net debt) implies EBITDA shrinking to ~$14.3b by 2035 (purple) from ~$16b today — the stock is priced as if policy permanently impairs earnings power, with zero credit for 2–3% volume growth or the buyback. That is why HCA sits at ~8x EV/EBITDA and ~12.5x earnings, near a 52-wk low, while the Street is at $480–530. The buyback is the quiet engine: ~5–8%/yr share shrink (222M→~146M base by 2035) compounds per-share value even in bear, which is why the downside rail still grinds higher long-term. Devil’s advocate: the bull/blue cases depend on a political act (subsidy extension) that may not come — base it on policy as legislated, not hope; ~3x leverage ($48b net debt) means the buyback is debt-funded, so a higher-rate or weaker-EBITDA world pinches both the buyback and coverage at once; the 2027 cliff is real and the mitigation math is management’s, unproven; DSH cuts and the 2028 provider-tax limits are separate headwinds stacked behind the ACA one; and a recession would hit volumes and uninsured/bad-debt together. Blue-sky “what has to be true”: subsidies extended (or made permanent) AND aging-demographic volume + commercial share gains + outpatient/ASC margin mix — a high-single-digit EBITDA compounder re-rating back toward 10x+ (~$2483).